Next Article in Journal
Assessment of Breast Cancer Surgery in Manitoba: A Descriptive Study
Previous Article in Journal
Implementation of the Canadian National Standards in Breast Cancer Surgical Care: Gaps, Barriers, Enablers and Opportunities
Open AccessCase Report

Safe Administration of Cemiplimab to a Kidney Transplant Patient with Locally Advanced Squamous Cell Carcinoma of the Scalp

by 1,* and 2,3
1
Department of Medicine (Oncology), Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York, NY 10467, USA
2
Department of Otorhinolaryngology-Head and Neck Surgery, Montefiore Medical Center, Bronx, New York, NY 10467, USA
3
Department of Pathology, Montefiore Medical Center, Bronx, New York, NY 10467, USA
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2021, 28(1), 574-580; https://doi.org/10.3390/curroncol28010057
Received: 6 December 2020 / Revised: 10 January 2021 / Accepted: 15 January 2021 / Published: 19 January 2021
Immunotherapies directed at T-cell activation through antibodies targeting checkpoint proteins, such as programmed cell death 1 (PD1), are rapidly becoming the new standard of care in the treatment of several malignancies. Cemiplimab is a monoclonal antibody targeting PD1 that has recently emerged as a highly active treatment for locally advanced and metastatic cutaneous squamous cell carcinoma (CSCC). Patients who have received an organ transplant (OTRs) have been traditionally excluded from clinical trials with checkpoint inhibitors (CIs), given concerns for organ rejection. Renal transplant recipients (RTRs) are more likely to develop cancers than the general population, and skin cancers are among the most frequent malignancies. We report the case of a 72-year-old man with a history of a kidney transplant who presented with a rapidly growing, locally advanced squamous cell carcinoma (SCC) of the scalp that recurred within four weeks from surgical resection. The patient was able to safely receive ten cycles of cemiplimab so far with significant clinical benefit, and no issues with his kidney function, while continuing immunosuppression with low dose prednisone alone. An ongoing clinical trial (NCT04339062) is further exploring the safety of CIs in patients with metastatic CSCC who have previously received allogeneic hematopoietic stem cell transplant or a kidney transplant. View Full-Text
Keywords: cemiplimab; cutaneous squamous cell carcinoma; kidney transplant; checkpoint inhibitor; PD1 cemiplimab; cutaneous squamous cell carcinoma; kidney transplant; checkpoint inhibitor; PD1
Show Figures

Figure 1

MDPI and ACS Style

Paoluzzi, L.; Ow, T.J. Safe Administration of Cemiplimab to a Kidney Transplant Patient with Locally Advanced Squamous Cell Carcinoma of the Scalp. Curr. Oncol. 2021, 28, 574-580. https://doi.org/10.3390/curroncol28010057

AMA Style

Paoluzzi L, Ow TJ. Safe Administration of Cemiplimab to a Kidney Transplant Patient with Locally Advanced Squamous Cell Carcinoma of the Scalp. Current Oncology. 2021; 28(1):574-580. https://doi.org/10.3390/curroncol28010057

Chicago/Turabian Style

Paoluzzi, Luca; Ow, Thomas J 2021. "Safe Administration of Cemiplimab to a Kidney Transplant Patient with Locally Advanced Squamous Cell Carcinoma of the Scalp" Curr. Oncol. 28, no. 1: 574-580. https://doi.org/10.3390/curroncol28010057

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop